EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Physicians' and pharmacists' perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics”

Wahram Andrikyan iD, Michael I Sponfeldner iD, Lea Jung-Poppe iD, Pauline Dürr iD, Melanie I Straubmeier, Anna K Schuster iD, Laura Weisbach iD, Katrin Farker, Michael Hartmann, Martin F Fromm iD, Renke Maas iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Wahram Andrikyan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Pharmacists, Physicians, Attitude of Health Personnel, Contraindications, Drug. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Previous work has identified several limitations in “Summaries of Product Characteristics” (SmPCs), which are associated with risks for patients. The aim of this study was to evaluate pharmacists' and physicians' interpretation of contraindications in SmPCs and reasons for their nonadherence in clinical routine.

Methods

For 20 commonly missed or ignored absolute contraindications, an anonymous online survey providing 24 clinical example cases (one or two per contraindication) for physicians and pharmacists was developed. Experts in medication safety were asked whether the respective case fulfilled the definition of the contraindication in the SmPC: (a) formally, irrespective of the clinical relevance of the contraindication (17 cases), and (b) whether the contraindication was deemed clinically relevant in each respective case (24 cases).

Results

Twenty‐seven pharmacists and 27 physicians completed the survey. For only one case (1/17; 5.8%) did all experts agree on the same answer option regarding the formal fulfilment of a given contraindication statement. Experts gave heterogeneous answers regarding the interpretation of a contraindication. For instance, among 10 predefined answer options for the contraindication “active liver disease” in the SmPC of simvastatin, every option was selected by at least six experts. In 17/24 (70.8%) clinical example cases a majority of experts agreed on the clinical relevance of a given contraindication. Key reasons for nonadherence to contraindications were “patient monitoring possible”, “lack of alternative treatment” and “acute/severe situations”.

Conclusions

Experts' disagreement on the interpretation of contraindications in SmPCs using clinical example cases indicates that further efforts are needed to improve their usability in clinical routine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacistsPhysiciansAttitude of Health PersonnelContraindications, DrugDrug LabelingDrug-Related Side Effects and Adverse ReactionsHumansSurveys and QuestionnairesMaleFemaleClinical Relevance

Stichwörter der Autor:innen

Summary of Product Characteristicscontraindicationdrug safetymedication errormedication safetyprescribing information

Autor:innen und Institutionen

  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Pharmacy Department, Erlangen University Hospital, Erlangen, Germany.
  • Hospital Pharmacy, University Center for Pharmacotherapy and Pharmacoeconomics, Jena University Hospital, Jena, Germany.
  • Department for Neurology, Jena University Hospital, Jena, Germany.
  • FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Wahram Andrikyan, Michael I Sponfeldner, Lea Jung-Poppe, Pauline Dürr, Anna K Schuster, Laura Weisbach, Martin F Fromm, Renke Maas

Förderung

  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Andrikyan, W., Sponfeldner, M. I., Jung-Poppe, L., Dürr, P., Straubmeier, M. I., Schuster, A. K., Weisbach, L., Farker, K., Hartmann, M., Fromm, M. F., & Maas, R. (2025). Physicians' and pharmacists' perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics”. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16331

Vancouver

Andrikyan W, Sponfeldner MI, Jung-Poppe L, Dürr P, Straubmeier MI, Schuster AK, et al. Physicians' and pharmacists' perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics”. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16331

BibTeX
@article{Andrikyan2025,
  author = {Andrikyan, Wahram and Sponfeldner, Michael I and Jung-Poppe, Lea and Dürr, Pauline and Straubmeier, Melanie I and Schuster, Anna K and Weisbach, Laura and Farker, Katrin and Hartmann, Michael and Fromm, Martin F and Maas, Renke},
  title = {Physicians' and pharmacists' perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics”},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16331}
}
Kostenlos starten →